Share
Ulrich Wendt
Alchemab Therapeutics, a UK-based biotech focused on antibody discovery, has appointed Ulrich Wendt, PhD MBA, as Chief Business Officer (CBO).
The appointment is aimed at strengthening and expanding the company’s partnerships with biopharma organizations to accelerate the development of novel antibody therapeutics.
Dr. Wendt brings more than a decade of experience in business development, with a strong track record of delivering high-value partnerships across multiple stages of the drug development pipeline. Known for his strategic and dealmaking capabilities, he is expected to play a key role in advancing Alchemab’s collaboration and licensing efforts.
Prior to joining Alchemab, Dr. Wendt served as Global Head of Business Development, Immunology at Sanofi. He also held leadership roles supporting business development across Sanofi’s diabetes and primary care units, while overseeing global search and evaluation as well as alliance management in cardiometabolic disease.
His appointment comes at a time of strong momentum for Alchemab, following recent pharma licensing agreements, an extension of its Series A funding, and the advancement of its first therapeutic asset into clinical trials in 2025 through a partnership with Eli Lilly and Company.
Alchemab leverages a proprietary platform combining one of the world’s largest antibody databases—derived from disease-resilient individuals—with an AI-powered search engine to identify protective antibodies. This approach has enabled the development of a broad pipeline targeting hard-to-treat diseases beyond the reach of traditional discovery methods.
